Company intelligence / Profile preview

Evit Asia

Taipei, Taiwan

Ownership: Private
Development stage: Other

Overview

Evit Asia is a biotechnology company specializing in exosome-based technologies for both diagnostic and therapeutic applications. Based in Taiwan, the company leverages its proprietary platform to isolate and characterize extracellular vesicles (EVs) for early cancer detection and targeted drug delivery. Their services include advanced exosome isolation, analysis, and the development of liquid biopsy tools such as Exo-Check. Beyond diagnostics, Evit Asia is pioneering exosome-based therapeutic platforms designed for targeted drug delivery and immunotherapy. By harnessing the natural communication capabilities of exosomes, the company seeks to provide non-invasive, highly specific tools for clinical diagnosis and precision treatment in oncology.

Therapeutic areas: Oncology
Modalities: Exosome-based therapyBiologicLiquid biopsy
Industry: Biotech

Beyond the preview

Go deeper on Evit Asia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evit Asia.

Explore the full profile